THOMAS MAMALAKIS: Open Payments
NPI 1346810173 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,290 in 129 payments from 17 companies in 2025. Trend: 2023 $3,481 · 2024 $2,879 · 2025 $2,290
Food & beverage: $2,290
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 14 | $363 |
| Vanda Pharmaceuticals Inc. | 11 | $318 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $251 |
| ABBVIE INC. | 15 | $204 |
| Neurocrine BioSciences, Inc. | 9 | $181 |
| E.R. Squibb & Sons, L.L.C. | 10 | $162 |
| Supernus Pharmaceuticals, Inc. | 22 | $142 |
| Collegium Pharmaceutical, Inc. | 8 | $137 |
| Axsome Therapeutics, Inc. | 4 | $114 |
| Bausch Health US, LLC | 5 | $100 |
Products named: ARISTADA, FANAPT, CAPLYTA, VRAYLAR, INGREZZA, COBENFY, Qelbree, Jornay PM.
Industry payments across VA — which companies pay providers there.
